


ALK⁺ ALCL with erythroblast-like cytology diagnosed in ascites in a patient with history of B-cell lymphomas

Hong Fang and Shaoying Li, The University of Texas MD Anderson Cancer Center



A 42-year-old woman with a history of marginal zone lymphoma (8 years ago) with diffuse large B-cell lymphoma transformation (4 years ago) was admitted with shortness of breath, bilateral pleural effusions, and ascites. A paracentesis of ascites was performed, and cytology smears showed many large-sized atypical cells with abundant basophilic cytoplasm and cytoplasmic vacuoles, resembling erythroblasts (panel A; objective 600×). Cell block hematoxylin and eosin staining showed numerous large atypical cells, some having horseshoe-like nuclei (panel B; objective 500×). By immunohistochemistry, the neoplastic cells were positive for CD30, anaplastic lymphoma kinase (ALK) (nuclear and cytoplasmic, indicating ALK rearrangement, likely *NPM1::ALK* translocation), CD2 (partial), CD4, CD45 (subset), and epithelial membrane antigen (subset), whereas they were negative for CD3, CD5, CD19, paired box 5,

CD138, Epstein-Barr virus–encoded small RNA, and human herpesvirus 8 (panels C-F; objective 400×). Flow cytometric analysis showed no monocytic B cells; instead, a large population of aberrant T cells was detected: positive for CD4, CD25, and CD30, and negative for CD3, CD5, CD7, and CD8 (panels G-H). She was diagnosed with ALK-positive anaplastic large-cell lymphoma (ALK⁺ ALCL), which was later confirmed with lymph node involvement.

ALK⁺ ALCL with erythroblast-like cytology first diagnosed in body fluid is highly unusual, especially in a patient with a previous history of B-cell lymphomas. Lack of history of ALCL with such an unusual morphology is diagnostically challenging. Careful morphologic examination and extensive immunophenotypic workup are critical in reaching the correct diagnosis.

Downloaded from http://ashpublications.net/blood/article-pdf/142/19/1672/2088454/blood_bld-2023-021876-main.pdf by guest on 18 May 2024